Statera BioPharma Common Stock

Statera BioPharma posts a common stock of $250K as of September 2022. That compares with $27M in the prior-year period — down 99.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Statera BioPharma's common stock was $27M. The latest reading is $250K — a 99.1% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Statera BioPharma's financial statement story. At $250K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for STAB's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Statera BioPharma's other metric pages and overview cover the third.

Judging Statera BioPharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $250K here, then scan peer and history charts to see if the gap is persistent.